Form 8-K - Current report:
SEC Accession No. 0001493152-24-043130
Filing Date
2024-10-31
Accepted
2024-10-31 06:31:23
Documents
15
Period of Report
2024-10-31
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 2.06: Material Impairments
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 50380
2 ex99-1.htm EX-99.1 13294
3 ex99-1_001.jpg GRAPHIC 8116
  Complete submission text file 0001493152-24-043130.txt   258155

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE mtnb-20241031.xsd EX-101.SCH 3039
5 XBRL LABEL FILE mtnb-20241031_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE mtnb-20241031_pre.xml EX-101.PRE 24181
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3720
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

EIN.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38022 | Film No.: 241412320
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)